“AACR”,2020-2024年历年AACR年会均有相关报道,具体如下表所示。 表2.3-12024年AACR年会PARP7相关摘要信息 序号具体摘要内容期刊/会议机构 Abstract7588:DiscoveryofNSP-5033:AnovelandpotentPARP7/12dual诺沃斯达药业有限公 1AACR2024 inhibitor司 Abstract4535:JAB-26766:Asmall-molecule,orallybioavailablePARP7北京加科...
Members must be in good standing in order to sponsor and endorse abstracts for presentation (see below for details). To be in good standing for the November 17 regular abstract deadline, member dues must be paid in full through 2022. To be in good standing for the January 12 late-breaking...
AACR 2024 苏州浦合医药科技有限公司 3 Abstract 7278:Discovery of a novel WRN inhibitor,ZM-3329 that efficiently inhibits MSI-H tumor growth AACR 2024 先声药业 4 Abstract 5942:Discovery of WRN inhibitors as targeted therapy in the treatment of microsatellite unstable(MSI-H)tumors AACR 2024 31、 ...
SKB-264:AACR肺癌/胃癌临床数据显著获益 2024年AACR会议上,科伦博泰展示了其靶向TROP2ADC药物SKB-264用于治疗非小细胞肺癌(NSCLC)和胃癌的临床数据。针对43名既往接受过治疗的晚期NSCLC患者总体人群,客观缓解率(ORR)为43.6%,中位无进展生存期(mPFS)和中位总生存期(mOS)分别达到7.2m和22.6m。其中,EGFR突变型较EGFR...
Scheduled Abstract Presentations as of April 1, 2023Download the PDF AACR2023 摘要征文投稿 重要日期: CALL FOR ABSTRACTS Regular Abstract Submission Opens: September 27, 2022 - 摘要征集开始 NextGen Stars Application Deadline: October 4, 2022
AACR 2024:KRAS抑制剂最新进展 药智头条 / 费翔 KRAS是癌症中最常见的基因突变之一,大约有三分之一的癌症携带KRAS突变。然而,由于该靶点表面平滑且缺乏理想的小分子结合位点,长期以来它一直被视为“不可成药”的靶点。 这一切在全球首个KRAS抑制剂Sotorasib(AMG 510)获得批准上市后发生了历史性的突破。但近期,其...
Frequency: Annual Country of Study: Any country Application Procedure: To be considered, please submit an electronic version of a dissertation abstract that is no longer than 15 double-spaced pages (including appendices, tables, figures, and references). Closing Date: 1 January Additional Information...
再鼎医药将于 2024 年 EORTC-NCI-AACR (ENA) 大会上公布靶向 DLL3阳性实体瘤的在研抗体偶联药物 (ADC) ZL-1310 的 1 期研究数据 2024年 10月 9日 将在全体会议期间通过口头报告讨论ZL-1310作为创新ADC的治疗潜力,其靶向的Delta样配体3(DLL3)是经验证的治疗小细胞肺癌(SCLC)的靶点 ZL-1310属于再鼎医药正在...